Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.
about
A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced diseaseLamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatmentsDevelopment of asthma is determined by the age-dependent host response to respiratory virus infection: therapeutic implicationsYeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.Implications of Age-Dependent Immune Responses to Enterovirus 71 Infection for Disease Pathogenesis and Vaccine Design.Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice.Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.Gamma interferon signaling in oligodendrocytes is critical for protection from neurotropic coronavirus infectionA respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.Gene expression differences in lungs of mice during secondary immune responses to respiratory syncytial virus infection.Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.Dengue.Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.Therapeutic targeting of respiratory syncytial virus G-protein.Development of a reverse genetics system for respiratory syncytial virus long strain and an immunogenicity study of the recombinant virus.Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccineRespiratory syncytial virus-like nanoparticle vaccination induces long-term protection without pulmonary disease by modulating cytokines and T-cells partially through alveolar macrophages.Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeuticsVirus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.Pre-existing virus-specific CD8(+) T-cells provide protection against pneumovirus-induced disease in mice.Specific dietary oligosaccharides increase Th1 responses in a mouse respiratory syncytial virus infection model.The Pneumonia Virus of Mice (PVM) model of acute respiratory infection.Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndromeRespiratory syncytial virus infection: from biology to therapy: a perspective.RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model.Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice.The host response and molecular pathogenesis associated with respiratory syncytial virus infection.Respiratory viruses and eosinophils: exploring the connections.Pulmonary eosinophils and their role in immunopathologic responses to formalin-inactivated pneumonia virus of mice.Eosinophils and their interactions with respiratory virus pathogens.Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease.Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.Viral infections in lung transplant recipients.Translational sciences approach to RSV vaccine development.Fc gamma receptors in respiratory syncytial virus infections: implications for innate immunity.Unmet needs in respiratory diseases : "You can't know where you are going until you know where you have been"--Anonymous.
P2860
Q21560951-08CF40A7-D1CF-4263-B213-49C510A4E4E0Q26830726-A6FB4361-C25A-4195-9E3A-C46089A0E974Q26991548-79980B6C-9911-4BC0-B7F8-548BE771C5FBQ30218075-EE7193E3-2036-4523-AC94-3548E49D5AEFQ30382068-3A03FCC3-099F-4E3E-8466-DCFE98AC8E70Q30423481-B9BDC7AF-B384-4F74-AEFE-23E27C4079FBQ33558356-F28502FE-7129-4B74-B07B-1E5863B98AB7Q33676538-4184BEB3-E994-462E-A0A5-BB94F2882329Q33690612-3DEBE3C4-9E4F-4D2D-8032-003B23EED274Q33760871-380053C1-9349-476A-B314-8FCBCE7C7F13Q34120191-B82EDC8D-5A01-4A31-969F-1E4B14A04B66Q34120278-D5E0E3AB-65B3-4576-9FE0-EEEC5B282C3BQ34125057-39CC62A7-7133-480D-B7E0-5E48944CCB4EQ34247261-34A24C78-B24A-4C19-95BD-B3F21F29DDCDQ34603346-AC858A8A-8320-4B98-8446-5E9EB2630BEAQ34624688-579B98E1-29FE-44C0-B653-ED930633C3DAQ34990420-69DD7161-D9AA-454F-BD26-7A7BE8688FE7Q35196230-CB491AEC-708A-46A0-BD9E-0087F32908E2Q35867712-4578AA4E-3687-4E2D-9073-7E53BA315AD8Q36174346-0A27ECC9-8AD3-4946-88E9-1D52E4E9E60BQ36281893-997CD491-E959-4400-91C7-B6E839013CC3Q36301296-9FFD7739-E33D-433A-93FB-3A8CD78E13DBQ36363236-7F5738B5-06F9-412F-86DF-650F34C7DDCCQ36482753-990FB3C5-D0A5-4096-A79D-04511CDF2BEFQ36650501-B8961EB9-3EA8-46FD-9DF9-D8E40BE189FDQ36834294-6FE74EA2-4800-44F6-9F93-6C19C707A465Q36994716-181B93D2-B212-46EA-8EFB-D8BAB50585BFQ37071608-17CA2FB4-AFF9-4869-886C-FD3ABF2925B0Q37147650-B410C906-E96B-40CA-9674-DC0F41A2ACD5Q37252618-ACBD3D12-C50C-4DC0-AB66-034B32495315Q37263779-36420ACD-DD4A-4F12-81B9-1DA127318160Q37340452-45FF483C-69A0-49B8-B0DB-FB15852AD9FCQ37369537-85FF7872-9792-4B69-A48A-EC219F8DD9BCQ37421366-E3015779-8952-4B34-89F6-5A9525C34DC3Q37649439-4818B1C1-F662-4D14-8CAF-A5FBAB2FA82FQ37713895-85948C41-8360-43DD-99CE-BBB8588BD3F7Q37721885-F711E428-DBDE-404E-AFEA-2B188DA170C3Q38140040-F32A45A6-5B66-4741-875F-5D579990B264Q38162418-71843BC6-B8D8-44FB-8761-B279453B53E2Q38167718-5F14D1BE-F09F-4644-9C46-C81E03B18CF6
P2860
Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.
@en
type
label
Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.
@en
prefLabel
Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.
@en
P2860
P1433
P1476
Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease
@en
P2093
Elaine M Castilow
Matthew R Olson
P2860
P2888
P304
P356
10.1007/S12026-007-0071-6
P577
2007-01-01T00:00:00Z